Market capitalization | $154.93m |
Enterprise Value | $194.41m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.09 |
P/S ratio (TTM) P/S ratio | 1.66 |
P/B ratio (TTM) P/B ratio | 6.96 |
Revenue growth (TTM) Revenue growth | -4.98% |
Revenue (TTM) Revenue | $86.82m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
4 Analysts have issued a Akoya Biosciences Inc forecast:
4 Analysts have issued a Akoya Biosciences Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 87 87 |
5%
5%
|
|
Gross Profit | 54 54 |
24%
24%
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -44 -44 |
31%
31%
|
Net Profit | -58 -58 |
19%
19%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery and clinical research. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers two distinct solutions, the CODEX and Phenoptics platforms, to serve the diverse needs of researchers across discovery, translational and clinical research. The company was founded by Garry Nolan, Yury Goltsev and Nikolay Samusik in 2015 and is headquartered in Menlo Park, CA.
Head office | United States |
CEO | Brian McKelligon |
Employees | 330 |
Founded | 2015 |
Website | www.akoyabio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.